Arcutis EVP & CMO sells shares under 10b5-1 plan

Arcutis Biotherapeutics executive Patrick Burnett, Executive Vice President and Chief Medical Officer, reported selling Arcutis common stock in two transactions.

Rhea-AI Filing Summary

Arcutis Biotherapeutics executive Patrick Burnett, Executive Vice President and Chief Medical Officer, reported selling Arcutis common stock in two transactions. On February 2, 2026, he sold 3,675 shares at a weighted average price of $25.4984 to cover tax withholding tied to vesting restricted stock units. On February 4, 2026, he sold 9,794 shares at a weighted average price of $25.8064. Both transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After these sales, Burnett directly beneficially owned 80,651 shares of Arcutis common stock.

Insider Trade Summary

Net Seller: 13,469 shares

Net Sell 2 txns

Insider Burnett Patrick

Role See Remarks

Sold 13,469 shs ($346K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,794	$25.8064	$253K
Sale	Common Stock	3,675	$25.4984	$94K

Holdings After Transaction: Common Stock — 80,651 shares (Direct)

Footnotes (4)

1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
4. F4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.58 to $26.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

FAQ

What insider stock transactions did Arcutis Biotherapeutics (ARQT) report?

Arcutis reported that executive Patrick Burnett sold common stock in two transactions. He sold 3,675 shares on February 2, 2026, at $25.4984 and 9,794 shares on February 4, 2026, at $25.8064, as disclosed in a Form 4 insider trading report.

Who is the insider involved in the latest ARQT Form 4 filing?

The insider is Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics. He reported two sales of common stock in early February 2026 and held 80,651 shares directly following the reported transactions, according to the Form 4 disclosure.

Why did Patrick Burnett sell Arcutis (ARQT) shares in February 2026?

One of Burnett’s sales represented shares sold to cover tax withholding obligations from vesting restricted stock units. The filing notes these RSUs were granted January 12, 2024, with 25% vesting annually starting February 1, 2025, conditioned on continued service to Arcutis.

Were the February 2026 ARQT insider sales under a 10b5-1 trading plan?

Yes. The Form 4 states the reported transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024. The plan has an end date of February 27, 2026, providing a pre-arranged framework for executing these stock sales.

How many Arcutis (ARQT) shares does Patrick Burnett own after the reported sales?

After the February 2026 transactions, Patrick Burnett directly beneficially owned 80,651 shares of Arcutis common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct equity stake following the two sales.

What price ranges applied to Patrick Burnett’s ARQT stock sales?

The reported prices are weighted averages for multiple trades. For the February 2, 2026 sale, prices ranged from $24.745 to $25.68. For the February 4, 2026 sale, prices ranged from $25.58 to $26.09, as detailed in the transaction footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		3,675	D	$25.4984(2)	90,445	D
Common Stock	02/04/2026		S(3)		9,794	D	$25.8064(4)	80,651	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.58 to $26.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's Title: Executive Vice President and Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.